

26 November 2025

RESULTS OF ANNUAL GENERAL MEETING

Bioxyne Limited (ASX:BXN) is pleased to advise that at the Annual General Meeting held on 26 November 2025, all resolutions were passed on a poll.

In accordance with Section 251AA(2) of the Corporations Act 2001 and Listing Rule 3.13.2 the details of the proxy votes lodged and poll are as attached.

Approved by the Board of Bioxyne Limited for release to the ASX.

Guy Robertson

Company Secretary



Bioxyne Limited

Appendix

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2

Resolution details		Instructions given to validly appointed proxies (as at proxy close)					Number of votes cast on the poll (where applicable)				Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Exclusions	Abstain	For	Against	Exclusions	Abstain*	Carried / Not Carried
1 Remuneration Report	Ordinary	502,943,845 78.17%	140,452,294 21.83%	0 0.00%	0	665,941,727	502,943,845 38.41%	140,452,294 10.73%	0	665,941,727	Carried
2 Re-election of Director – Mr Anthony Ho	Ordinary	1,168,761,842 99.33%	7,911,124 0.67%	0 0.00%	0	132,664,900	1,168,761,842 89.26%	7,911,124 0.60%	0	132,664,900	Carried
3 Approval of Issue of Performance Rights to Samuel Watson	Ordinary	528,178,795 78.74%	142,625,277 21.26%	0 0.00%	0	638,533,794	528,178,795 40.34%	142,625,277 10.89%	0	638,533,794	Carried
4 Approval of Issue of Performance Rights to Jason Hine	Ordinary	528,178,795 78.74%	142,625,277 21.26%	0 0.00%	0	638,533,794	528,178,795 40.34%	142,625,277 10.89%	0	638,533,794	Carried
5 Ratification of Placement Shares - Listing Rule 7.1A	Ordinary	1,173,802,179 99.98%	202,470 0.02%	0 0.00%	0	135,333,217	1,173,802,179 89.65%	202,470 0.02%	0	135,333,217	Carried
6 Ratification of Placement Options - Listing Rule 7.1	Ordinary	1,173,802,179 99.98%	202,470 0.02%	0 0.00%	0	135,333,217	1,173,802,179 89.65%	202,470 0.02%	0	135,333,217	Carried
7 Approval to issue shares and options to Anthony Ho to enable his subscription in the March Placement	Ordinary	1,149,238,712 99.98%	180,687 0.02%	0 0.00%	0	159,918,467	1,149,238,712 87.77%	180,687 0.01%	0	159,918,467	Carried
8 Approval to issue shares and options to Jason Hine to enable his subscription in the March Placement	Ordinary	1,174,860,247 99.98%	180,687 0.02%	0 0.00%	0	134,296,932	1,174,860,247 89.73%	180,687 0.01%	0	134,296,932	Carried
9 Ratification of Broker Options	Ordinary	1,176,478,369 99.98%	232,970 0.02%	0 0.00%	0	132,626,527	1,176,478,369 89.85%	232,970 0.02%	0	132,626,527	Carried
10 Approval of Additional 10% Placement Capacity	Special	1,160,567,388 88.64%	148,604,544 11.35%	0 0.00%	0	165,934	1,160,567,388 88.64%	148,604,544 11.35%	0	165,934	Carried

*votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.



For further information, please contact:

Bioxyne Limited

Sam Watson
Chief Executive Officer
info@bioxyne.com

NWR Communications

Melissa Tempra
Media & Investor Relations
melissa@nwrcommunications.com.au

About Bioxyne Limited

Bioxyne Limited is a licensed Australian pharmaceutical and healthcare company manufacturing and distributing novel medicines, health products and active pharmaceutical ingredients including medicinal cannabis, MDMA, and Psilocybin.

About Breathe Life Sciences

Breathe Life Sciences ("BLS") is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company's corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, health products, and prescription-only cannabis medicines.
- b) Contract drug manufacturing and white label manufacturing of scheduled medicines, therapeutic goods, medical devices, consumer health products, and active pharmaceutical ingredients. BLS manufactures over 200 of Australia's medicinal cannabis brands.
- c) Import, export, and wholesale of active pharmaceutical ingredients, starting materials, patient-ready medicinal products, and/ or consumer health products in Australia, Japan, UK, USA and Europe.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®



- United Kingdom: drwatsoncbd.com
- UK / EU: breathelifesciences.com

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com